Skip to main content
. 2018 Feb 26;9(21):15658–15672. doi: 10.18632/oncotarget.24585

Figure 2. Ribociclib treatment leads to G1 arrest and decreased BrdU incorporation.

Figure 2

(A) Representative cell cycle profiles of Hey1 ovarian cancer cells treated with Ribociclib for 72 h and (B) summary of cell cycle phase shifts. (C) BrdU incorporation in Hey1 ovarian cancer cells after 72 h of treatment with the indicated doses of Ribociclib. All samples were analyzed in triplicate with each experiment replicated at least once. FACS samples counted at least 10,000 events. *p < 0.05, ** p < 0.01, ***p < 0.001 by two-sample, two-sided t-test.